However, the translation of antigen-specific Treg therapies for autoimmune diseases into the clinic remains challenging and most studies using oral insulin treatments for tolerization in T1D conducted so far failed to meet their primary outcome (18, 19). This evidence concerns the gene INS and type 1 diabetes mellitus.